The Company symbol change is part of an overall corporate communication strategy to convey the Company's expanding business plan and establish its global market identity.

Calvin C. Cao, Chairman and CEO of Stem Cell Therapy International, stated: "Our Company is proud of its achievements to date and of becoming a publicly listed company and looks forward to achieving its business plan goals and our mission objectives. We are excited that our company's new symbol (SCII) will be reflected in all the public markets."

Stem Cell Therapy International's mission is to make available its stem cell products to treatment facilities around the world, so that patients suffering from biological and neurological disorders, previously deemed incurable by traditional medicine, may find a solution to their disabling and crippling conditions within the new field of stem cell transplantation therapy. Our products include biological solutions containing embryonic stem cells, adult stem cells and stem cells which are extracted from umbilical cord blood.

Chairman Cao further explained, "In the future we plan to introduce a number of different cures and treatments, and develop vertical markets in all aspects of stem cell use, which will improve the quality of life for thousands of patients around the world, much sooner than later."

Stem cell transplantation (SCT) therapy is a field of medicine, which uses techniques and technologies that rely on replacing diseased, damaged or dysfunctional cells with healthy, functioning ones. This therapy is similar to the process of organ transplantation, only the treatment consists of the transplantation of stem cells into the body rather than entire organs, thus eliminating any chance of rejection or the need for expensive and potentially dangerous immunosuppression drug therapy. These new techniques are being applied to finding a cure for a wide range of human disorders, including neurological diseases such as Alzheimer's, Parkinson's Disease, ALS, (which is also commonly known as Lou Gehrig's disease), leukemia, muscular dystrophy, multiple sclerosis, arthritis, spinal cord injuries, brain injury, stroke, heart disease, liver and retinal disease, diabetes as well as certain types of cancer and helps alleviate the side effects of chemotherapy.

With the enactment of Proposition 71 in California in November 2004, a fund of $3 billion was created to fund stem cell research. Since then four other states: New Jersey, Connecticut, Illinois and Wisconsin, have allocated funds for stem cell research. Among the leading public companies in the U.S. in the field of stem cell technology are A.C.T. Holdings, Inc.; ViaCell; Geron; StemCells, Inc.; and Aastrom Biosciences Inc. For additional information, please visit our website @ www.scticorp.com.